Clinical Trials
8 trialsNCT06881992 2026-05-18
Tumor HI
Rezolute
Phase 3 Recruiting
NCT03583528 2026-05-12
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Active not recruiting
NCT07262970 2025-12-04
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Rezolute
Available
NCT00427349 2023-07-05
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT04915144 2023-02-21
177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
British Columbia Cancer Agency
Phase 2 Withdrawn
NCT02831179 2017-09-28
Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn
NCT00131911 2014-11-17
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Phase 2 Completed